OncoMatch/Clinical Trials/NCT07795749
Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
Is NCT07795749 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Paclitaxel Q2W and Paclitaxcel Q3W for esophageal carcinoma.
Treatment: Paclitaxel Q2W · Paclitaxcel Q3W — This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis. These are subjects who have a proven primary carcinoma of the digestive tract..
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Esophageal Carcinoma
Gastric Cancer
Colorectal Cancer
Disease stage
Metastatic disease required
peritoneal cytology positive disease or peritoneal carcinomatosis detected by imaging, laparoscopy or laparotomy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: iterative intraperitoneal therapy (HIPEC, PIPAC, NIPEC)
Exception: Single exposure to HIPEC at the time of cytoreduction is not an exclusion
History of prior iterative intraperitonealtherapy administered either as HIPEC, PIPAC or NIPEC. Single exposure to HIPEC at the time of cytreduction is not an exclusion
Lab requirements
Blood counts
Leukocytes: ≥ 2,000/mcL; Absolute neutrophil count: ≥ 1,500/mcL (may receive gcsf); Platelets: ≥ 70,000/mcl (may receive TPO); Hemoglobin: > 8.0 g/dL (may be transfused); Serum albumin: ≥ 2.5 g/dL
Kidney function
Creatinine: < 2 X institutional upper limit of normal
Liver function
Total bilirubin: within 2x of normal institutional limit; AST(SGOT)/ALT(SPGT): ≤5 X institutional upper limit of normal
Adequate organ and marrow function as defined below: Leukocytes: ≥ 2,000/mcL; Absolute neutrophil count: ≥ 1,500/mcL (may receive gcsf); Platelets: ≥ 70,000/mcl (may receive TPO); Total bilirubin: within 2x of normal institutional limit; AST(SGOT)/ALT(SPGT): ≤5 X institutional upper limit of normal; Creatinine: < 2 X institutional upper limit of normal; Hemoglobin: > 8.0 g/dL (may be transfused); Serum albumin: ≥ 2.5 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07795749 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior iterative intraperitoneal therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages